Literature DB >> 17885675

Effect of RNA oligonucleotide targeting Foxo-1 on muscle growth in normal and cancer cachexia mice.

C-M Liu1, Z Yang, C-W Liu, R Wang, P Tien, R Dale, L-Q Sun.   

Abstract

Foxo-1, a member of the Foxo forkhead type transcription factors, is markedly upregulated in skeletal muscle in energy-deprived states such as fasting, cancer and severe diabetes. In this study, we target the Foxo-1 mRNA in a mouse skeletal myoblast cell line C2C12 and in vivo models of normal and cancer cachexia mice by a Foxo-1 specific RNA oligonucleotide. Our results demonstrate that the RNA oligonucleotide can reduce the expression of Foxo-1 in cells and in normal and cachectic mice, leading to an increase in skeletal muscle mass of the mice. In search for the possible downstream target genes of Foxo-1, we show that when Foxo-1 expression is blocked both in cells and in mice, the level of MyoD, a myogenic factor, is increased while a muscle negative regulator GDF-8 or myostatin is suppressed. Taken together, these results show that Foxo-1 pays a critical role in development of muscle atrophy, and suggest that Foxo-1 is a potential molecular target for treatment of muscle wasting conditions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17885675     DOI: 10.1038/sj.cgt.7701091

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  32 in total

Review 1.  The "O" class: crafting clinical care with FoxO transcription factors.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

Review 2.  FoxO transcription factors: their roles in the maintenance of skeletal muscle homeostasis.

Authors:  Anthony M J Sanchez; Robin B Candau; Henri Bernardi
Journal:  Cell Mol Life Sci       Date:  2014-05       Impact factor: 9.261

Review 3.  Corticosteroids and muscle wasting: role of transcription factors, nuclear cofactors, and hyperacetylation.

Authors:  Per-Olof Hasselgren; Nima Alamdari; Zaira Aversa; Patricia Gonnella; Ira J Smith; Steven Tizio
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2010-07       Impact factor: 4.294

4.  Increased circulating myostatin in patients with type 2 diabetes mellitus.

Authors:  Fang Wang; Yonggan Liao; Xuefeng Li; Chunlin Ren; Changming Cheng; Yongsheng Ren
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-08-11

5.  NF-κB but not FoxO sites in the MuRF1 promoter are required for transcriptional activation in disuse muscle atrophy.

Authors:  Chia-Ling Wu; Evangeline W Cornwell; Robert W Jackman; Susan C Kandarian
Journal:  Am J Physiol Cell Physiol       Date:  2014-02-19       Impact factor: 4.249

Review 6.  Cachexia in chronic heart failure: endocrine determinants and treatment perspectives.

Authors:  Norman Mangner; Yae Matsuo; Gerhard Schuler; Volker Adams
Journal:  Endocrine       Date:  2012-08-19       Impact factor: 3.633

Review 7.  A fork in the path: Developing therapeutic inroads with FoxO proteins.

Authors:  Kenneth Maiese; Jinling Hou; Zhao Zhong Chong; Yan Chen Shang
Journal:  Oxid Med Cell Longev       Date:  2009 Jul-Aug       Impact factor: 6.543

Review 8.  New strategies for Alzheimer's disease and cognitive impairment.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Oxid Med Cell Longev       Date:  2009 Nov-Dec       Impact factor: 6.543

9.  Leptin administration favors muscle mass accretion by decreasing FoxO3a and increasing PGC-1alpha in ob/ob mice.

Authors:  Neira Sáinz; Amaia Rodríguez; Victoria Catalán; Sara Becerril; Beatriz Ramírez; Javier Gómez-Ambrosi; Gema Frühbeck
Journal:  PLoS One       Date:  2009-09-04       Impact factor: 3.240

Review 10.  Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology.

Authors:  Kenneth Maiese; Jinling Hou; Zhao Zhong Chong; Yan Chen Shang
Journal:  ScientificWorldJournal       Date:  2009-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.